Peripheral nerve functional recovery after nerve injury generally requires multiple growth factors by synergistic effect. However, the optical combination of multiple synergistic growth factors for axonal regeneration has been scarcely considered up to now. Meanwhile, the use of growth factors in promoting nerve regeneration was limited by its short biological half-life in vivo, its vulnerability to structure disruption or hydrolyzation, leading to loss of bioactivity. Herein, a novel polymeric nanoparticle delivery system composed of heparin and ε-poly-L-lysine (PL) was prepared for control release of nerve growth factor (NGF) and basic fibroblast growth factor (bFGF). The nanoparticles were synthesized by polyelectrolyte complexation in aqueous solution at room temperature, followed by cross-linking with biological genipin. The obtained nanoparticles had a spherical shape, with a mean diameter of about 246 nm, and high growth factors encapsulation efficiency as well as good stability. NGF and bFGF were encapsulated in the nanoparticles and showed a continuous and slow release behavior in vitro. The bioactivities of the released growth factors were evaluated, and exhibited the synergistic effect. The controlled release of the dual synergistic growth factors would improve the treatment of peripheral nerve injury to mimic the natural cellular microenvironments. control release, nerve growth factor, basic fibroblast growth factor, nanoparticles
Peripheral nerve injury is a critical and devastating condition that is usually caused by traumatic injury and often results in life-long disability, for example, permanent functional and sensory deficits [1] . When the long peripheral nerve defect cannot be repaired by end-to-end suturing, a nerve graft between the proximal and distal nerve stumps is often necessary for promoting the nerve regeneration [1,2]. The representative nerve graft selection is an autologous nerve graft self-donated from another part of the body. However, this recognized gold standard technique compared with other treatments for peripheral nerve repair is limited by the inherent drawbacks, such as secondary injury at the donor site, tissue availability, formation of neuroma, and the mismatch between nerve and graft in tissue structure and size [3] . To overcome these disadvantages of autologous nerve graft, various biochemical engineering of nerve guidance conduits based on artificial or natural materials has emerged as an alternative choice to bridge nerve gaps [46] . These guidance conduits have significant merits in peripheral nerve repair, such as no need for a second surgery, assistance in guiding the regenerating axons from the proximal to distal stumps and minimizing the infiltration of fibrous scar tissue [7] . At present, these nerve guidance conduits for the treatment of peripheral nerve injuries have limited functional capacity to repair short nerve defect [8] . However, this method often results in the deficient clinical results or the entire failure of nerve regeneration in the case of longer nerve gap. One of the main causes of the poor clinical nerve regeneration is inadequate growth factors support in the nerve regeneration microenvironments [9] . Accordingly, increasing functional requirements for nerve conduit become necessary since they should not only serve as a desirable support but also a satisfactory carrier to achieve suitable functional recovery for long nerve defect. For improving the function of nerve guides, the bioactive strategy containing growth factors is investigated to mimic the natural cellular microenvironments [10, 11] .
Growth factors are naturally occurring proteins and polypeptides that could stimulate the cellular survival, proliferation and differentiation [12] . Growth factors also play an important role for neuronal survival and axonal regeneration via the binding to specific classes of tyrosine kinase receptors existing on the surface of the responsive cells, which is a prerequisite for effective reinnervation of the injured nerves [1, 13] . They have been widely used in tissue engineering approaches for the repair of peripheral nerve injuries and nerve defects. Two of the attractive factors are nerve growth factor (NGF) and basic fibroblast growth factor (bFGF). NGF could promote the growth, maintenance and survival of sensory and motor neuron, and regulate the synthesis of protein and metabolism of sugar and fat in the neuron [14] . bFGF is a representative member of the heparin-binding growth factors, and could promote the survival and neurite extension of neurons from the central nervous system in vitro, stimulating proliferation of the glial cells such as astrocytes, oligodendrocytes, and schwann cells [15, 16] . Much evidence has indicated that after nerve injury the local presence of growth factor at the injury sites plays a vital and complex role in controlling the survival, proliferation, migration and differentiation of various cell types involved in nerve regeneration [17] . Additionally, recent studies demonstrated that the optimal combination of multiple growth factors elicits synergistic effect on axonal regeneration in vitro and in vivo [18] . It could be ascribed to that single factor treatment may not be optimal as nerves generally comprise different neuronal subpopulations that depend on different growth factors. However, the optical combination of multiple synergistic growth factors for axonal regeneration has been scarcely considered up to now.
The growth factors could be generally delivered by direct injection or release from a carrier. When the growth factors were administrated by direct injection, their applications were limited by their short biological half-life in vivo, their vulnerability to structure disruption or hydrolyzation, leading to loss of bioactivity at the defect site [19] . Moreover, growth factors also show minimal tissue penetration which may result in ineffective delivery at the defect site [20] . Among the strategies developed to improve protein's bioavailability and absorption, the use of colloidal carriers, especially nanoparticle delivery carriers, is an emerging strategy under investigation [21] . Compared with the direct administration, the growth factors encapsulated within the carriers can be more efficiently used than free growth factors, and therefore, the amount of growth factors required can be reduced. Furthermore, nanoparticle drug delivery carriers, owing to their sub-cellular and sub-micron size, could easily penetrate into tissues and fine capollaries and control the dosage and delivery period of biomolecules with the purpose of enhancing the efficacy of the growth factors [22] . These drug delivery systems are developed not only to improve the biological utilization of growth factors by controlling drug release to the target site, but also to protect their bioactivity from degradation by direct exposure to the harsh environments. Therefore, increasing interests and intensive efforts have been devoted to biomedical drug delivery carriers composed of biodegradable and biocompatible natural polymer at the nanoscale.
In this study, a novel polymeric nanoparticle delivery system composed of heparin and ε-Poly-L-lysine (PL) was prepared for control release of the growth factors. The heparin-PL nanoparticles were synthesized by polyelectrolyte complexation in aqueous solution at room temperature, followed by cross-linking with biological genipin. The nanoparticles were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM) and scanning electron microscopy (SEM). NGF and bFGF were loaded in the nanoparticles with high encapsulation efficiency and showed a continuous and slow release behavior in vitro. The bioactivities of the released growth factors were evaluated by the number of neurite-bearing PC12 cells. It is demonstrated that two growth factors could elicit the synergistic effect on the neurite growth of PC12 cells.
Materials and methods

Materials
ε-Poly-L-lysine (PL, n=2535) was purchased from Zhejiang Silver Elephant Bioengineering Co., Ltd. (China). Heparin (Mw, 600020000) was bought from Shanghai Yuanye Reagent Company. Genipin was supplied by Shanghai Aladdin Reagent Company. Nerve growth factor 7.0s (NGF) was purchased from EMD Millipore Corporation. Recombinant human basic fibroblast growth factor (bFGF) was purchased from PeproTech, Inc (Rocky Hill, USA). Mouse NGF enzyme-linked immunosorbent assay (ELISA) kit and human bFGF ELISA kit were purchased from Shanghai Yuanye Reagent Company, China. All other reagents were of analytical purity grade and used without further purification.
Preparation of heparin-PL nanoparticles
In a typical run, PL solution (1 mL of a 3 mg mL 1 aqueous solution) was added dropwise to 2 mL of heparin aqueous solution (3 mg mL 1 ) under stirring, and the mixture was stirred for 1 h at room temperature. Genipin (2.3 mg) was then added to the reaction system at room temperature and cross-linked for 12 h. After cross-linking, the aggregates were removed by passing the solution through a 0.22 μm filter. The nanoparticles were collected by centrifugation at 10000 r min 1 and redispersed in the predetermined volume of distilled water.
Preparation of growth factors loaded nanoparticles
Briefly, PL solution (1 mL of a 3 mg mL 1 aqueous solution containing NGF (0.5 μg) and bFGF (0.5 μg)) was added dropwise to 2 mL of heparin aqueous solution (3 mg mL 1 )
under stirring, and the mixture was stirred for 1 h at room temperature. Genipin (2.3 mg) was then added to the reaction system at room temperature and cross-linked for 12 h. After cross-linking, the aggregates were removed by passing the solution through a 0.22 μm filter. The nanoparticles were collected by centrifugation at 10000 r min 1 and redispersed in the predetermined volume of distilled water. Similarly, the bFGF loaded nanoparticles or NGF loaded nanoparticles were prepared by adding PL solution containing 1 μg bFGF or 1 μg NGF to the heparin solution and cross-linked as described above.
Characterization of nanoparticles
Particle size of the nanoparticles we carried out using a dynamic light scattering instrument (Brookhaven Instruments Corporation, USA). Each sample of the nanoparticles was adjusted to a concentration of 0.05% (w/v) in filtered water or 0.01 mol L 1 NaCl solution in the case of zeta potential examination. All analyses were performed in triplicate at 25°C and the results were the average of the three runs. The morphology of prepared nanoparticles was examined by transmission electron microscopy (TEM; JEOL JEM-1010). 10 μL of the nanoparticle suspension was placed onto a 200-mesh carbon-coated copper grid for 2 min, and after air-drying the samples were observed. Scanning electron microscopy (SEM) observations were performed on HITACHI S-4800.
Growth factor encapsulation efficiency
The encapsulation efficiency of growth factors in the nanoparticles with different formations was determined by centrifuging the nanoparticle suspension at 10000 r min 1 at 4°C for 30 min. The amount of growth factor in clear supernatant was determined using the ELISA using a preestablished calibration curve. The encapsulation efficiency was calculated by the following formulas:
Encapsulation efficiency % weight of growth factor in the nanoparticles weight of the feeding growth factor 
In vitro release of the growth factors loaded nanoparticles
A suspension of the growth factors loaded nanoparticles in water was dialyzed against 10 mL of phosphate buffer solution (PBS, 0.01 mol L 1 ) with different pH values at 37°C.
After a predetermined period, 1 mL aliquots was withdrawn and the nanoparticles were centrifuged at 10000 r min 1 at 4°C for 30 min. The growth factor concentration in sampled release medium was determined by ELISA using a pre-established calibration curve. The measurements were performed in triplicate and the results were the average of the three times.
In vitro cytotoxicity
The cytotoxicity of samples were tested by using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Rat Schwann cell line (RSC-96) cells were grown in a Dulbecco's modified Eagle's medium (DMEM) with 2 mmol L 1 glutamine, 100 U mL 1 penicillin and 100 µg mL 1 streptomycin. The culture medium was supplemented with 10 % fetal bovine serum in a 5% CO 2 atmosphere at 37°C. The cells were seeded into a 96-well plate, and incubated with 100 µL of culture medium containing a series of doses of samples at 37°C for 24 h. After incubation, the culture media in each well were removed and cells were washed three times with PBS. Then, 20 µL of MTT solutions (5 mg mL 1 ) was added to each well and cultured for another 4 h. The supernatant was discarded and 100 µL of DMSO was added to each well. The A values of plates were observed on a microplate reader at 570 nm (Safire, Tecan, Switzerland).
NGF and bFGF bioactivity by PC12 cell bioassay
Rat PC12 cells were grown in DMEM with 2 mmol L 1 glutamine, 100 U mL 1 penicillin and 100 µg mL 1 streptomycin. The culture medium was contained with 10% horse serum and 5% fetal bovine serum in a 5% CO 2 atmosphere at 37°C. Prior to differentiation of the PC12 cells, the well plate was coated with poly-L-lysine overnight. The cells were seeded into a 24-well plate and incubated with the culture medium at 37°C cultured for 7 d. The culture medium consisted of DMEM medium supplemented with various samples: control group, blank nanoparticles, NGF (100 ng mL 1 ), NGF loaded nanoparticles (NGF, 100 ng mL 1 ), bFGF (100 ng mL 1 ), bFGF loaded nanoparticles (bFGF, 100 ng mL 1 ), NGF+bFGF (NGF, 100 ng mL 1 ; bFGF, 100 ng mL 1 ) and NGF+bFGF loaded nanoparticles (NGF, 100 ng mL 1 ; bFGF, 100 ng mL 1 ). Fresh growth factor formulations were added to the media every two days.
Immunocytochemistry
Cultured cells were fixed in freshly prepared 4% paraformaldehyde for 10 min at room temperature, and then permeabilized with 0.1% triton X-100/PBS for 15 min. After washing three times with PBS for 10 min, the cells were blocked with 10% BSA (blocking buffer) for 45 min at room temperature. Cells were incubated with mouse monoclonal β-tubulin III and rabbit anti-neurofilament (NF) 200 IgG fraction of antiserum for 2 h followed by further reaction with Alexa Fluor 488 donkey anti-mouse IgG and Alexa Fluor 594 donkey anti-rabbit IgG. Afterwards, the cells were stained by DAPI for 10 min. Representative fluorescent images were observed using a Leika fluorescence microscope.
Results and discussion
Preparation of heparin-PL nanoparticles
In order to develop the effective method to deliver growth factors, a reaction nanoparticulate system was selected in aqueous solution consisting of a cationic biomacromolecule, PL, and an anionic biomacromolecule, heparin. Due to their well-established properties, such as water-solubility, biodegradability and high biocompatibility, PL and heparin were chosen as the starting material in the design of vectors for growth factors delivery [23, 24] . Furthermore, heparin could have specific affinity with many growth factors and then has been widely utilized for growth factor delivery to optimize and extend the growth factor delivery kinetics, prevent their degradation and enhance binding to cell surface receptors [25, 26] . Additionally, it was previously reported that heparin improves the axonal growth in the peripheral nerve injury [27] . The heparin-PL nanoparticles were prepared by polyelectrolyte complexation and covalent cross-link with genipin in aqueous solution at room temperature, as schematically shown in Figure 1A . The driving force of the formation of the nanoparticles can be ascribed to the complexation through the intermolecular electrostatic interaction between the polycationic PL with the polyanionic heparin. Subsequently, the nanoparticles were crosslinked by biological genipin, which is superior to traditional crosslinking agents in terms of lower cytotoxicity and has proven to have neuritogenic activity and neuroprotective effects [28, 29] .
Characterization of heparin-PL nanoparticles
The mean hydrodynamic diameter of the obtained nanoparticles was determined to be 246 nm in aqueous medium of pH 7.4 by DLS ( Figure 1B) , suggesting that the particles are well dispersed in aqueous solution. The morphology and structure of the formed nanoparticles were examined by TEM and SEM (Figure 2 ). It can be seen that all of the na- noparticles exhibited a spherical shape with a narrowly distributed diameter of 230 nm, which is smaller than the hydrodynamic diameter determined by DLS due to the dry state in the TEM observation.
To confirm the chemical structure of the particles, Fourier transform infrared (FTIR) spectroscopic analysis of PL, heparin and PL-heparin nanoparticles was performed. Figure 3 shows the FTIR spectra of PL, heparin, genipin cross-linked PL-heparin nanoparticles. In the spectrum of PL, the characteristic peak at 1673 cm 1 corresponds to the carbonyl stretching of secondary amide (amide I band) and a peak at 1560 cm 1 is attributed to the N-H bending vibrations. The peaks located at 3402 and 1620 cm 1 could be assigned to the hydroxyl stretching vibration and the carbonyl stretching vibration, respectively. The spectrum of the PL-heparin nanoparticles had characteristic peaks similar to the parent molecules. However, some minor changes in the spectrum were observed, for example, the absorption band at 1673 and 1620 cm 1 became wider in the nanoparticles.
These data indicated significant ionic interaction between the PL and heparin molecules.
In vitro release from nanoparticles
Considering that the heparin could bind a multitude of growth factors and maintain their bioactivity for an extended period of time [30] , the PL-heparin nanoparticles seem to be very appropriate to be the carriers for growth factor delivery. To evaluate the potential of PL-heparin nanoparticles as a drug delivery system, the growth factors were loaded into the nanoparticles. Consequently, we successfully encapsulated the NGF and bFGF into the nanoparticles by their specific binding with heparin. PL solution containing growth factors was added to heparin solution to prepare the particles, and then the particles were cross-linked with genipin. A satisfactory encapsulation efficiency of NGF and bFGF was found to be about 98.1% and 99.3%, respectively. The size distribution of growth factor loaded particles did not significantly change compared with that of the unloaded nanoparticles (data not shown), since the ratio of growth factor in the particles is small. The in vitro release of growth factors from nanoparticles was examined. Figure 4 shows the cumulative in vitro release profiles up to 20 days of growth factors from the particles in release medium at 37°C. A sustained and no initial burst in vitro release profile of growth factors (NGF and bFGF) from the particles was observed, which may be ascribed to the strong binding between particles and growth factors. Since heparin has specific affinity with many growth factors, such as NGF and bFGF, the mechanism for growth factor release from particles is quite different from that of physically or electrostatically encapsulating growth factors which usually have much larger initial burst from the nanoparticles [31] . For the bFGF, ~42.5% of the loaded growth factor was released from particles within 20 days. However, ~59.4% of the loaded growth factor was released from particles within 20 days for the NGF. This phenomenon can be attributed to the different binding constants between heparin and growth factors (bFGF has the high affinity binding with proteoglycan heparin via specific electrostatic interaction. However, NGF has the low affinity with proteoglycan heparin) [32, 33] . This result suggests that growth factors loaded nanoparticles show a continuous and slow release behavior for NGF and bFGF.
In vitro cytotoxicity of nanoparticles
To examine the cytotoxicity of the growth factors loaded nanoparticles, the in vitro cytotoxicity tests against the RSC-96 cells were conducted. The RSC-96 cells were cultivated in the DMEM culture medium with various concentrations of nanoparticles for 24 h ( Figure 5 ). It is found that the viability of RSC-96 cells cultured in the nanoparticle solution was not significantly different from that in DMEM supplemented with 10% fetal calf serum (blank control), which indicated that the nanoparticles have no obvious cytotoxic effect at all used conditions. However, the viability of cells cultured with the medium containing growth factors loaded nanoparticles is higher than that of the nanoparticle group, since the growth factor may promote the survival and proliferation of schwann cells. Furthermore, the cells that were observed with optical microscopy after 12 h in culture in the solution were still active. Bright-field images show that all cells proliferate very well and maintain their normal configuration at all used conditions (data not shown).
In vitro bioactivity of nanoparticles
To examine whether the released growth factors is still biologically active, the in vitro bioactivity tests of growth factors against PC12 cells were conducted. PC12 cells originated from pheochromocytoma of a rat adrenal medulla, sprout neuritis and differentiate into sympathetic ganglion-like cell in response to growth factors. Therefore, this model is usually used to evaluate the neuronal differentiation. The neurite outgrowth of PC12 cells was investigated by counting the number of neurite-bearing PC12 cells ( Figure  6 ). After seven days culture, the percentage of neuritebearing (differentiated) cells treated with blank nanoparticles or DMEM medium is small. When cells were treated with growth factor, the percentage of neurite-bearing cells increased dramatically. Interestingly, the percentage of neurite-bearing cells treated with combination of bFGF and NGF has the highest ratio in all used groups. The synergistic effect of the combined growth factors enables the higher neurite-bearing percentage. Meanwhile, the cells treated with the growth factor loaded nanoparticles exhibited similar results. However, the nanoparticle group showed a little lower percentage than free growth factors at equal concentration after seven days culture at the tested concentration. This phenomenon can be attributed to the sustained release property of growth factors loaded nanoparticles.
To confirm the differentiation from PC12 cells to the neuronal cell phenotype, the cultured cells were fixed and immunostained with two neuronal markers, β-tubulin III and NF200 ( Figure 7 ). It is shown that PC12 cells treated with blank nanoparticles and control group have not differentiated to sympathetic ganglion-like cells. In contrast, significant differentiation appears when PC12 cells were treated with growth factor or growth factor loaded nanoparticles. The neurite length of PC12 cells treated with combination of NGF and bFGF was longer than that of cells treated with single growth factor. The neurite length of PC12 cells treated with NGF is longer than that treated with bFGF [34] . Additionally, the nanoparticle groups displayed the similar trends concerning the percentage of neurite-bearing cells treated with nanoparticles. The immunocytochemical analysis indicated that combination of NGF and bFGF has synergistic effect on the differentiation of PC12 cells. 
Conclusion
The novel polymeric nanoparticle delivery system composed of heparin and PL was prepared for controlled release of NGF and bFGF. The nanoparticles were fabricated by polyelectrolyte complexation method, followed by crosslinking with biological genipin. NGF and bFGF were encapsulated in the nanoparticles and show a continuous and slow release behavior in vitro. The bioactivity of the released growth factors was evaluated, and exhibited the synergistic effect. The controlled release of the dual synergistic growth factors would improve the treatment of peripheral nerve injury to mimic the natural cellular microenvironments.
